Triheptanoin oil

DRUG2 trials

Sponsors

University of Texas Southwestern Medical Center, Institut National de la Santé Et de la Recherche Médicale, France

Conditions

Congestive Heart FailureHuntington DiseaseNon-ischemic Cardiomyopathy

Phase 1

Study of the Acute Effects of Triheptanoin in Heart Failure

WithdrawnNCT01787851

University of Texas Southwestern Medical CenterCongestive Heart Failure, Non-ischemic Cardiomyopathy

Start: 2013-02-28End: 2014-02-28Updated: 2018-12-14

Phase 2

A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease

CompletedNCT02453061

Institut National de la Santé Et de la Recherche Médicale, FranceHuntington Disease

Start: 2015-06-29End: 2019-12-03Updated: 2026-06-03

Related Papers

Effect of Triheptanoin on Caudate Atrophy and Motor Scores in Patients With Early-Stage Huntington Disease: A Phase II Study.

2024-12-30

J01 Triheptanoin is associated with clinical stability and decreased caudate atrophy in huntington disease

2021-09-012 citations

Huntington’s Disease Clinical Trials Corner: August 2018

Journal of Huntington s Disease2018-06-0131 citations

Huntington’s Disease Clinical Trials Corner: February 2018

2018-01-0144 citations